Immune if Pharma partnering with Bristo-Myers for clinical trial study of Berilimumab drug treatment on bulliou pemphigoid. $150 million up front, 270 million in mile stones payment, $15 a share after FDA approval.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.